Page 56 - 《中国药房》2024年20期

[J]. CA Cancer J Clin，2024，74（3）：229-263. 249-256.
[ 2 ] GARRIDO-CASTRO A C，LIN N U，POLYAK K. Insights [13] LI J B，JIANG Z F. Chinese Society of Clinical Oncology
into molecular classifications of triple-negative breast Breast Cancer（CSCO BC）guidelines in 2022：stratifica‐
cancer：improving patient selection for treatment[J]. tion and classification[J]. Cancer Biol Med，2022，19（6）：
Cancer Discov，2019，9（2）：176-198. 769-773.
[ 3 ] GOLDENBERG D M，CARDILLO T M，GOVINDAN S [14] WU B，ZHANG Q，SUN J. Cost-effectiveness of nivolumab
V，et al. Trop-2 is a novel target for solid cancer therapy plus ipilimumab as first-line therapy in advanced renal-
with sacituzumab govitecan（IMMU-132），an antibody- cell carcinoma[J]. J Immunother Cancer，2018，6（1）：124.
drug conjugate（ADC）[J]. Oncotarget，2015，6（26）： [15] LOIBL S，LOIRAT D，TOLANEY S M，et al. Health-
22496-22512. related quality of life in the phase Ⅲ ASCENT trial of
[ 4 ] RUGO H S，BARDIA A，MARMÉ F，et al. Sacituzumab sacituzumab govitecan versus standard chemotherapy in
govitecan in hormone receptor-positive/human epidermal metastatic triple-negative breast cancer[J]. Eur J Cancer，
growth factor receptor 2-negative metastatic breast cancer 2023，178：23-33.
[J]. J Clin Oncol，2022，40（29）：3365-3376. [16] 胡善联. 中国医保药品价格谈判回顾和展望[J]. 卫生经
[ 5 ] WU Y L，HU S S，LIU X L，et al. Cost-effectiveness of 济研究，2024，41（1）：9-13.
sacituzumab govitecan versus single-agent chemotherapy HU S L. Review and prospects of medical insurance price
for metastatic triple-negative breast cancer：a trial-based negotiation in China[J]. Health Econ Res，2024，41（1）：
analysis[J]. Cost Eff Resour Alloc，2024，22（1）：32. 9-13.
[ 6 ] 刘国恩. 中国药物经济学评价指南2020[M]. 北京：中国 [17] SHI D M，LI Y，LIANG X Y，et al. Cost-effectiveness of
市场出版社，2020：36-46. sacituzumab govitecan in hormone receptor-positive/
LIU G E. Chinese pharmacoeconomic evaluation guide‐ human epidermal growth factor receptor 2-negative meta‐
lines 2020[M]. Beijing：China Market Publishing House， static breast cancer[J]. Front Oncol，2023，13：1162360.
2020：36-46. [18] LANG Y T，CHAI Q Q，TAO W Q，et al. Cost-
[ 7 ] HAGIWARA Y，OHASHI Y，UESAKA K，et al. Health- effectiveness of sacituzumab govitecan versus chemo‐
related quality of life of adjuvant chemotherapy with S-1 therapy in advanced or metastatic triple-negative breast
versus gemcitabine for resected pancreatic cancer：results cancer[J]. Breast，2023，68：173-180.
from a randomised phase Ⅲ trial（JASPAC 01）[J]. Eur J [19] CHEN J G，HAN M Y，LIU A H，et al. Economic evalua‐
Cancer，2018，93：79-88. tion of sacituzumab govitecan for the treatment of meta‐
[ 8 ] GUYOT P，ADES A E，OUWENS M J，et al. Enhanced static triple-negative breast cancer in China and the US[J].
secondary analysis of survival data：reconstructing the Front Oncol，2021，11：734594.
data from published Kaplan-Meier survival curves[J]. [20] XIE J，LI S N，LI Y M，et al. Cost-effectiveness of sacitu‐
BMC Med Res Methodol，2012，12：9. zumab govitecan versus chemotherapy in patients with
[ 9 ] WOODS B S，SIDERIS E，PALMER S，et al. Partitioned relapsed or refractory metastatic triple-negative breast
survival and state transition models for healthcare deci‐ cancer[J]. BMC Health Serv Res，2023，23（1）：706.
sion making in oncology：where are we now? [J]. Value [21] CHER B P，GOH S，AZIZ M I A，et al. Cost-utility analy‐
Health，2020，23（12）：1613-1621. sis of sacituzumab govitecan versus chemotherapy for the
[10] RAUTENBERG T，HODGKINSON B，ZERWES U，et treatment of metastatic triple-negative breast cancer in
al. Meta-analysis of health state utility values measured by Singapore[J]. Expert Rev Pharmacoecon Outcomes Res，
EuroQol 5-dimensions（EQ-5D）questionnaire in Chinese 2024，24（2）：217-225.
women with breast cancer[J]. BMC Cancer，2022， [22] WAN X M，PENG L B，LI Y J. A review and comparison
22（1）：52. of methods for recreating individual patient data from pub‐
[11] 中国临床肿瘤学会. 肿瘤放化疗相关中性粒细胞减少症 lished Kaplan-Meier survival curves for economic evalua‐
规范化管理指南[J]. 中华肿瘤杂志，2017，39（11）： tions：a simulation study[J]. PLoS One，2015，10（3）：
868-878. e0121353.
Chinese Society of Clinical Oncology. Guidelines for stan‐ [23] XU B H，MA F，WANG T，et al. A phase Ⅱb，single arm，
dardized management of neutropenia induced by chemo‐ multicenter trial of sacituzumab govitecan in Chinese
therapy and radiotherapy[J]. Chin J Oncol，2017，39（11）： patients with metastatic triple-negative breast cancer who
868-878. received at least two prior treatments[J]. Int J Cancer，
[12] DRANITSARIS G，YU B，KING J，et al. Nab-paclitaxel， 2023，152（10）：2134-2144.
docetaxel，or solvent-based paclitaxel in metastatic breast （收稿日期：2024-04-26 修回日期：2024-09-22）
cancer：a cost-utility analysis from a Chinese health care （编辑：孙 冰）
perspective[J]. Clinicoecon Outcomes Res，2015，7：

· 2498 · China Pharmacy 2024 Vol. 35 No. 20 中国药房 2024年第35卷第20期